Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration.

Campieri C, Campieri M, Bertuzzi V, Swennen E, Matteuzzi D, Stefoni S, Pirovano F, Centi C, Ulisse S, Famularo G, De Simone C.

Kidney Int. 2001 Sep;60(3):1097-105.

2.

[Hyperoxaluria and renal calculi].

Buño Soto A, Torres Jiménez R, García Puig J, Mateos Antón F.

Arch Esp Urol. 1996 Sep;49(7):707-26. Review. Spanish.

PMID:
9020008
3.

Oxalate-degrading bacteria of the human gut as probiotics in the management of kidney stone disease.

Abratt VR, Reid SJ.

Adv Appl Microbiol. 2010;72:63-87. doi: 10.1016/S0065-2164(10)72003-7. Review.

PMID:
20602988
4.
5.

Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria?

Hoppe B, von Unruh G, Laube N, Hesse A, Sidhu H.

Urol Res. 2005 Nov;33(5):372-5. Epub 2005 Nov 13. Review.

PMID:
16284877
6.

[Oxaluria in urinary lithiasis].

Thomas J, Charransol G, Barthelemy C, Thomas E, Legrand JC, Desgrez P, Steg A.

Presse Med. 1983 Sep 17;12(32):1991-4. Review. French.

PMID:
6225103
7.

A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease.

Siva S, Barrack ER, Reddy GP, Thamilselvan V, Thamilselvan S, Menon M, Bhandari M.

BJU Int. 2009 Jan;103(1):18-21. doi: 10.1111/j.1464-410X.2008.08122.x. Epub 2008 Nov 18. Review.

8.

The management of patients with enteric hyperoxaluria.

Asplin JR.

Urolithiasis. 2016 Feb;44(1):33-43. doi: 10.1007/s00240-015-0846-5. Epub 2015 Dec 8. Review.

PMID:
26645872
9.

Oxalate metabolism and renal calculi.

Menon M, Mahle CJ.

J Urol. 1982 Jan;127(1):148-51. Review.

PMID:
7035692
10.

Hyperoxaluric calcium nephrolithiasis.

Asplin JR.

Endocrinol Metab Clin North Am. 2002 Dec;31(4):927-49. Review.

PMID:
12474639
11.

The role of intestinal oxalate transport in hyperoxaluria and the formation of kidney stones in animals and man.

Whittamore JM, Hatch M.

Urolithiasis. 2017 Feb;45(1):89-108. doi: 10.1007/s00240-016-0952-z. Epub 2016 Dec 2. Review.

PMID:
27913853
12.

Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria.

Hoppe B, Leumann E, von Unruh G, Laube N, Hesse A.

Front Biosci. 2003 Sep 1;8:e437-43. Review.

PMID:
12957811
13.

Probiotics and other key determinants of dietary oxalate absorption.

Liebman M, Al-Wahsh IA.

Adv Nutr. 2011 May;2(3):254-60. doi: 10.3945/an.111.000414. Epub 2011 Apr 30. Review.

14.

[Oxalobacter formigenes--characteristics and role in development of calcium oxalate urolithiasis].

Torzewska A.

Postepy Hig Med Dosw (Online). 2013 Nov 27;67:1144-53. Review. Polish.

15.

Enteric and mild hyperoxaluria.

Sutton RA, Walker VR.

Miner Electrolyte Metab. 1994;20(6):352-60. Review.

PMID:
7783697
16.

The role of the microbiome in kidney stone formation.

Mehta M, Goldfarb DS, Nazzal L.

Int J Surg. 2016 Dec;36(Pt D):607-612. doi: 10.1016/j.ijsu.2016.11.024. Epub 2016 Nov 12. Review.

PMID:
27847292
17.

Microorganisms and calcium oxalate stone disease.

Goldfarb DS.

Nephron Physiol. 2004;98(2):p48-54. Review.

PMID:
15499215
18.

Lowering urinary oxalate excretion to decrease calcium oxalate stone disease.

Holmes RP, Knight J, Assimos DG.

Urolithiasis. 2016 Feb;44(1):27-32. doi: 10.1007/s00240-015-0839-4. Epub 2015 Nov 27. Review.

19.

Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?

Peck AB, Canales BK, Nguyen CQ.

Urolithiasis. 2016 Feb;44(1):45-50. doi: 10.1007/s00240-015-0845-6. Epub 2015 Dec 8. Review.

PMID:
26645869
20.

Oxalate synthesis, transport and the hyperoxaluric syndromes.

Williams HE, Wandzilak TR.

J Urol. 1989 Mar;141(3 Pt 2):742-9. Review.

PMID:
2645433

Supplemental Content

Support Center